DEGRO statement on the KEYNOTE-689 trial: Perioperative immunotherapy in combination with adjuvant (chemo-)radiotherapy for resectable locally advanced head and neck cancers
- Study type
- Other
- Study name
- DEGRO statement on KEYNOTE-689
- Design
- Expert statement by the head and neck cancer expert panel of the German Society for Radiation Oncology (DEGRO) on the KEYNOTE-689 trial (not the primary trial report)
- Source
- Strahlenther Onkol · 2026
In plain words
This is a statement from a group of German radiotherapy experts about a clinical trial. Its topic is the use of immunotherapy before and after surgery, together with radiotherapy (with or without chemotherapy), for advanced head and neck cancers that can be operated on. Talk to your treating doctor to decide on the right treatment for you.
Treatment arms and regimens
Dosing details in the full text.
Source of the regimen details: No abstract in the PubMed record; dosing details in the full text
Doses are given for the information of specialists, as in this study’s protocol, and are not a prescription. Every drug must be prescribed by the treating physician for the individual patient.
Study population
The PubMed record has no abstract. Based on the title, the statement concerns resectable locally advanced head and neck cancers. Inclusion criteria are not in the available record and should be taken from the full text of the statement.
Endpoints
The PubMed record has no abstract and does not state endpoints. Details in the full text.
Safety and side effects
No safety information in the available record. Details in the full text.
Clinical significance and place in guidelines
The available record has no abstract, so the results and recommendations of the statement cannot be extracted from it. It can only be said that a DEGRO expert panel has taken a position on perioperative immunotherapy combined with adjuvant (chemo-)radiotherapy in these patients. The exact recommendations and level of evidence should be checked in the full text, together with the published correction. The status of approvals and clinical guidelines should also be checked separately.
Limitations
This card is based only on the PubMed record, which lacks an abstract, numerical data and recommendations. Before publication, the content should be completed from the full text and the correction and reviewed by an oncologist. The authors declared several conflicts of interest with pharmaceutical companies (including MSD and Merck).
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.